Can a precision-health startup finally bridge the gap between neuroscience and daily wellness and make cognitive longevity a mainstream priority? The leaders of brain health and wellness company BEVIMI today announced the launch of their company as part of the inaugural CG Well Summit. Convened by leading independent, full-service financial services firm Canaccord Genuity Group, this global summit unites thought leaders and key deal makers in the consumer health and wellness space. This morning’s opening keynote was delivered by BEVIMI Co-Founder and President Joel Dudley, Ph.D.
Kicking off the summit, Dudley’s “Wellness 3.0: Charting a New Path for Personalized and Preventative Health” talk addressed the transition from sick care to true health care that BEVIMI is designed to lead. Drawing from his vast qualifications and experiences, Dudley revealed how AI, precision health, and advanced diagnostics can finally unlock lasting outcomes and empower people to thrive.
Later today, BEVIMI Co-Founder and CEO Paul Jacobson will join the summit’s “Demonstrable Consumer Outcomes: Proof Over Promises and the Brands Driving Outcomes” expert panel discussion. As the former CEO of Thorne HealthTech, Jacobson led the company through 15 years of expansion — growing sales roughly 10 times, taking the venture public, then steering its go-private transaction. For this panel, he will join leaders in women’s health, longevity, gut, and brain health who are delivering real outcomes and making science-backed solutions accessible.
BEVIMI’s Mission and Future
Serving its mission of becoming a global leader in the advancement of cognitive longevity, BEVIMI is being built on a foundation of scientific rigor, innovation, and preventative health. Together with a rapidly growing staff representing proven leaders in the field, from their headquarters in Greenwich, Connecticut, Jacobson and Dudley are actively developing a platform for products focused on targeting neuroinflammation and cognitive performance across multiple indications and markets.
Today, the company is also revealing key details about its first product, which is currently slated for launch early next year. Designed as nutritional support for individuals at high risk of — or in preclinical stages of — Alzheimer’s disease, the product represents a breakthrough in cognitive health innovation. While a solid scientific foundation already exists for the product’s individual ingredients, it will enter an Institutional Review Board-approved, randomized, double-blind, placebo-controlled clinical study over the months ahead. The study’s primary objective is safety and tolerability, while secondary and exploratory measures will assess changes across a pre-specified biomarker panel relevant to Alzheimer’s pathophysiology.
According to BEVIMI’s co-founders, cognitive decline is a multifaceted process that requires addressing several underlying mechanisms simultaneously. Their flagship product aims to be the first of its kind to deliver clinically validated, bioactive ingredients, including hard-to-deliver hydrophobic compounds, at meaningful levels in a conveniently dosed 2-ounce beverage.
“Brain health is the new heart health,” Jacobson began. “Consumers are elevating cognitive wellness to a daily priority, and the underlying science has matured. BEVIMI’s first formulation is a multi-ingredient systems approach, intentionally mapped to four well-characterized pathways in Alzheimer’s biology. Each component was selected based on convergent human safety data and preclinical evidence, with attention to bioavailability, blood brain barrier engagement proxies, and complementary mechanism of action. We founded BEVIMI with leading scientists to bring pharmaceutical-style rigor — target mapping, dose justification, and pre-specified endpoints — to evidence-informed nutrition.”
“Starting soon,” Dudley added, “BEVIMI will begin providing science-based nutritional support, education, and AI-driven insights to help people who are seeking proactive solutions for cognitive decline. Long term, our proprietary technology and focus on dampening neuroinflammation, supporting amyloid-beta (Aβ) proteostasis and clearance, reinforcing blood-brain barrier integrity, and optimizing gut-microbiome-derived metabolites that influence brain signaling, will support improved outcomes across a wide spectrum of cognitive challenges, including focus, mood, sleep, and mental acuity.”
With its debut at the CG Well Summit, BEVIMI enters the wellness and brain health market with a strong scientific foundation and a clear commitment to supporting cognitive longevity for people worldwide.
